Avanos Medical (AVNS) 10-Q20 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information Document	9 Months Ended
Document and Entity Information Document	Sep. 30, 2014	Nov. 19, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'HALYARD HEALTH, INC.	'
Entity Central Index Key	'0001606498	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	46,535,951

CONDENSED_COMBINED_INCOME_STAT

CONDENSED COMBINED INCOME STATEMENT (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Net Sales (including related party sales of $24.8, $24.5, $70.4 and $69.0)	$408.50	$419.50	$1,232.70	$1,246.20
Cost of products sold (including related party purchases of $23.2, $21.5, $65.0 and $62.5)	276.3	258	840.6	789.3
Gross Profit	132.2	161.5	392.1	456.9
Research and development expenses	8.5	8.9	26.1	24.2
Selling and general expenses	111.3	82.5	298.1	266.9
Other (income) and expense, net	-0.7	-0.2	-2.4	-1.9
Operating Profit	13.1	70.3	70.3	167.7
Interest income	1	0.7	2.9	1.8
Interest expense	-0.1	0	-0.1	-0.2
Income Before Income Taxes	14	71	73.1	169.3
Provision for income taxes	-21.4	-23.1	-43.6	-54.5
Net (Loss) Income	($7.40)	$47.90	$29.50	$114.80

CONDENSED_COMBINED_INCOME_STAT1

CONDENSED COMBINED INCOME STATEMENT (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net sales	$408.50	$419.50	$1,232.70	$1,246.20
Cost of products sold	276.3	258	840.6	789.3
Kimberly Clark and Affiliates \| Affiliated entity	'	'	'	'
Net sales	24.8	24.5	70.4	69
Cost of products sold	$23.20	$21.50	$65	$62.50

CONDENSED_COMBINED_STATEMENT_O

CONDENSED COMBINED STATEMENT OF COMPREHENSIVE INCOME Statement (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net (Loss) Income	($7.40)	$47.90	$29.50	$114.80
Other Comprehensive (Loss) Income, Net of Tax	'	'	'	'
Unrealized currency translation adjustments	-9.2	1.6	-5.4	-12.4
Cash flow hedges	-0.3	-1.3	3.9	-5.6
Total Other Comprehensive (Loss) Income, Net of Tax	-9.5	0.3	-1.5	-18
Comprehensive (Loss) Income	($16.90)	$48.20	$28	$96.80

CONDENSED_COMBINED_BALANCE_SHE

CONDENSED COMBINED BALANCE SHEET (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$58.40	$44.10
Accounts receivable, net	192.2	203.3
Inventories	294.7	285.6
Current deferred income taxes and other current assets	50.8	52.1
Total Current Assets	596.1	585.1
Property, Plant and Equipment, Net	292.8	324.9
Goodwill	1,429	1,430.10
Other Intangible Assets	116.3	141.2
Other Assets	15.2	2.7
TOTAL ASSETS	2,449.40	2,484
Current Liabilities	'	'
Debt payable within one year (including related party debt of $10.9 and $9.1)	10.9	11.9
Trade accounts payable	118.4	118.5
Accrued expenses	148.6	180
Total Current Liabilities	277.9	310.4
Long-Term Liabilities	92.5	94.5
TOTAL LIABILITIES	370.4	404.9
Invested Equity	'	'
Kimberly-Clark's net investment	2,100.10	2,098.70
Accumulated other comprehensive loss	-21.1	-19.6
Total Invested Equity	2,079	2,079.10
TOTAL LIABILITIES AND INVESTED EQUITY	$2,449.40	$2,484

CONDENSED_COMBINED_BALANCE_SHE1

CONDENSED COMBINED BALANCE SHEET (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Debt payable within one year	$10.90	$11.90
Kimberly Clark and Affiliates \| Affiliated entity	'	'
Debt payable within one year	$10.90	$9.10

CONDENSED_COMBINED_CASH_FLOW_S

CONDENSED COMBINED CASH FLOW STATEMENT (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating Activities	'	'
Net income	$29.50	$114.80
Depreciation and amortization	61.6	52.6
Share-based compensation charged by Kimberly-Clark	5.1	4.7
Provision for losses on accounts receivable and inventories	0.1	1.6
Deferred income taxes	-13.9	-0.7
Asset impairment	41.9	0
Net losses on asset dispositions	3.5	1.6
Changes in operating working capital:	'	'
Decrease (increase) in accounts receivable	10.9	-5.4
(Increase) decrease in inventories	-9.1	2.1
Increase in trade accounts payable	7	7.8
Decrease in accrued expenses	-23.6	-24.1
Decrease in accrued income taxes	-3.9	-4.9
Other	-1.8	-3
Cash Provided by Operating Activities	107.3	147.1
Investing Activities	'	'
Capital spending	-60.4	-37.9
Cash outflows for acquisitions and investments	0	-2.2
Cash Used in Investing Activities	-60.4	-40.1
Financing Activities	'	'
Debt proceeds	1.9	0
Debt repayments	-2.9	-52.7
Change in Kimberly-Clark's net investment	-34.8	-62.2
Other	3.4	2.4
Cash Used in Financing Activities	-32.4	-112.5
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.2	1.6
Increase (Decrease) in Cash and Cash Equivalents	14.3	-3.9
Cash and Cash Equivalents - Beginning of Period	44.1	47.9
Cash and Cash Equivalents - End of Period	$58.40	$44

Accounting_Policies

Accounting Policies	9 Months Ended
Accounting Policies	Sep. 30, 2014
Accounting Policies [Abstract]	'
Accounting Policies	'
	Accounting Policies
	Background and Basis of Presentation
	Halyard Health, Inc. is a global business which seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. Our products and solutions are designed to address some of today’s most important healthcare needs, namely, preventing infections and reducing the use of narcotics while helping patients move from surgery to recovery. We market and support the efficacy, safety and economic benefit of our products with a significant body of clinical evidence.
	References to “Halyard,” “we,” “our” and “us” refer to the health care operations that relate to Kimberly-Clark's health care business. References to “Kimberly-Clark” mean Kimberly-Clark Corporation, a Delaware corporation, and its subsidiaries, other than Halyard, unless the context otherwise requires. Dollar amounts are reported in millions, except per share amounts, unless otherwise noted.
	In November 2013, Kimberly-Clark announced that its Board of Directors authorized management to evaluate a potential tax-free spin-off of its health care business (the “Spin-off”). Halyard Health, Inc. was incorporated in Delaware on February 25, 2014 for the purpose of holding the health care business following the separation. A Form 10 initial registration statement was filed in May 2014 with the Securities and Exchange Commission (“SEC”) to register our business as a stand-alone public company. The Form 10 registration statement, as amended, was declared effective by the SEC on October 17, 2014. The Spin-off was completed on October 31, 2014 and Kimberly-Clark’s health care business became Halyard Health, Inc. During the three and nine months ended September 30, 2014, $35 and $61, respectively, was recorded in selling and general expenses for transaction costs associated with the spin-off. See Note 2, “Separation from Kimberly-Clark and Long-Term Debt” for further discussion.
	These unaudited condensed combined interim financial statements represent the global operations of Kimberly-Clark's health care business, and have been prepared on a carve-out basis from the operations of Kimberly-Clark’s health care business. The combined financial statements are derived from Kimberly-Clark's consolidated financial statements and accounting records, and reflect our financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected.
	Annual Goodwill Impairment Test
	Goodwill is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. For 2014 we have completed the required annual testing of goodwill for impairment for all reporting units using the beginning of the third quarter 2014 as the measurement date. The fair value for all reporting units was in excess of the book value. The fair value of our Medical Devices unit exceeded the carrying value of its net assets by 76%; the fair value of our Surgical and Infection Prevention (“S&IP”) unit exceeded the carrying value of its net assets by 6%, primarily because of the incremental stand-alone public company corporate and ongoing costs described in Note 2 “Separation from Kimberly-Clark and Long-Term Debt” under the heading “Stand-Alone Public Company Costs.”
	The fair value determination utilized key assumptions regarding growth of the business and stand-alone public company corporate and ongoing costs, each of which required significant management judgment, including estimated future sales volumes, selling prices and costs, changes in working capital, and investments in property and equipment. These assumptions and estimates were based upon our historical experience and projections of future activity. In addition, the selection of the discount rate used to determine fair value was based upon current market rates and our current cost of financing. There can be no assurance that the assumptions and estimates made for purposes of the annual goodwill impairment test will prove to be accurate. Volatility in the equity and debt markets, or increases in interest rates, could result in a higher discount rate. Changes in sales volumes, selling prices and costs of goods sold, additional stand-alone public company costs, and increases in interest rates could cause changes in our forecasted cash flows. Unfavorable changes in any of the factors described above could result in a goodwill impairment charge in the future.
	New Accounting Standards
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The standard is effective for public entities for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The effects of this standard on our financial position, results of operations and cash flows are not yet known.

Separation_from_KimberlyClark_

Separation from Kimberly-Clark and Long-Term Debt	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Separation from Kimberly-Clark and Long-Term Debt	'
	Separation from Kimberly-Clark and Long-Term Debt
	Separation from Kimberly-Clark
	Prior to the Spin-off, Halyard Health, Inc. had no operations other than those related to the preparation to receive the health care business of Kimberly-Clark. Following the Spin-off, we became a separate public company, and Kimberly-Clark has no continuing stock ownership in us.
	Prior to the Spin-off, we entered into a distribution agreement and various other agreements with Kimberly-Clark to effect the separation of our business from Kimberly-Clark's other businesses and set forth our contractual relationships with Kimberly-Clark after the Spin-off. These agreements provide for the allocation, between us and Kimberly-Clark, of Kimberly-Clark's assets, employees, liabilities and obligations (including Kimberly-Clark’s investments, property and employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after the Spin-off. The various other agreements include a transition services agreement, a tax matters agreement, an employee matters agreement, intellectual property agreements and manufacturing and supply agreements.
	Using $250 of proceeds from 6.25% senior unsecured notes and $390 from a senior secured term loan (see “Senior Unsecured Notes, Term Loan and Revolving Credit Facilities” below) and cash on hand we made a cash distribution to Kimberly-Clark equal to the estimated amount of all of our available cash on the Spin-off date in excess of a defined minimum amount that we were to retain, or $680.
	Stand-Alone Public Company Costs
	Upon the Spin-off, we assumed responsibility for all of our stand-alone public company costs, including the costs of corporate services provided by Kimberly-Clark prior to the Spin-off. The corporate services provided to us include executive management, supply chain, information technology, legal, finance and accounting, investor relations, human resources, risk management, tax, treasury and other services. We estimate that our aggregate annual expense for these costs will be $146, including incremental expenses of $40 per year of cash expense and $11 per year of additional depreciation and amortization expense. In addition, as a result of the separation and Spin-off we expect to incur additional ongoing net expenses that we estimate will be approximately $29 on an annual basis related primarily to: (1) a decline in purchasing scale; (2) stranded facility costs as a result of excess manufacturing capacity in certain facilities, underutilization of certain of our distribution facilities and inefficiencies in shipping costs; and (3) a reduction in related party sales.
	In addition, as a result of the separation and Spin-off, we expect to incur $60 to $75 of transitional costs after the Spin-off through 2016 to establish our own capabilities as a stand-alone entity. These costs are related primarily to the transition services we expect to receive from Kimberly-Clark, as well as our branding and other supply chain transition costs.
	Senior Unsecured Notes, Term Loan and Revolving Credit Facilities
	Prior to the Spin-off, we issued $250 aggregate principal amount of 6.25% senior unsecured notes due October 15, 2022 (the “Notes”). The Notes will mature on October 15, 2022 and interest will accrue at a rate of 6.25% per annum from October 17, 2014 and will be payable semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2015.
	The agreement governing the Notes contains covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to:

	•	incur additional indebtedness, guarantee indebtedness or issue disqualified stock or, in the case of our restricted subsidiaries, preferred stock;

	•	pay dividends on, repurchase or make distributions in respect of our capital stock;

	•	make certain investments or acquisitions;

	•	sell, transfer or otherwise convey certain assets;

	•	create liens;

	•	enter into agreements restricting certain subsidiaries’ ability to pay dividends or make other intercompany transfers;

	•	consolidate, merge, sell or otherwise dispose of all or substantially all of our and our subsidiaries’ assets;

	•	enter into transactions with affiliates; and

	•	prepay certain kinds of indebtedness.
	Upon the Spin-off, we entered into a credit agreement establishing credit facilities in aggregate principal amount of $640, including a five-year senior secured revolving credit facility allowing borrowings of up to $250, with a letter of credit sub-facility in an amount of $75 and a swingline sub-facility in an amount of $25 (the “Revolving Credit Facility”), and a seven-year senior secured term loan of $390 (the “Term Loan Facility”). The Term Loan Facility is secured by substantially all of our assets located in the United States and the credit agreement contains covenants similar to those described above.
	Borrowings under the Term Loan Facility will bear interest, at Halyard’s option, at either (i) a reserve-adjusted LIBOR rate plus 3.25%, or (ii) a base rate (calculated as the greatest of (1) the prime rate, (2) the U.S. federal funds effective rate plus 0.50% and (3) the one month LIBOR Rate plus 1.00%) plus 2.25%. The Term Loan Facility requires quarterly amortization payments equal to 0.25% of the aggregate principal amount of the term loans outstanding on the closing date.
	Borrowings under the Revolving Credit Facility will bear interest, at Halyard’s option, at either (i) a reserve-adjusted LIBOR rate, plus a margin initially equal to 2.25% and then, following Halyard’s delivery under the credit agreement of Halyard’s financial statements for Halyard’s fiscal quarter ending March 31, 2015, ranging between 1.75% to 2.50% per annum, depending on Halyard’s consolidated total leverage ratio, or (ii) the base rate plus a margin initially equal to 1.25% and then, following Halyard’s delivery of those financial statements, ranging between 0.75% to 1.50% per annum, depending on Halyard’s consolidated total leverage ratio. The unused portion of Halyard’s Revolving Credit Facility will be subject to a commitment fee equal to (i) 0.25% per annum, when Halyard’s consolidated total leverage ratio is less than 2.25 to 1.00 and (ii) 0.40% per annum, otherwise.

Manufacturing_Footprint_Strate

Manufacturing Footprint Strategic Changes	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Manufacturing Footprint Strategic Changes	'
	Manufacturing Footprint Strategic Changes
	In June 2014, Kimberly-Clark initiated a plan to exit one of the disposable glove facilities in Thailand and outsource the related production to improve the competitive position of the S&IP business. The restructuring is expected to result in a reduction of our workforce by approximately 3,000 positions.
	The plan is expected to be completed by December 31, 2015 and result in estimated cumulative charges of $70 ($50 after-tax) over that period. We anticipate that the charges will consist of a non-cash asset impairment and accelerated depreciation charges of $55 and workforce reduction and other exit cash costs of $15.
	Through September 30, 2014, cumulative pre-tax charges for the manufacturing footprint strategic changes were $55 ($38 after-tax), consisting the following:


		Three Months Ended September 30, 2014			Nine Months Ended September 30, 2014
	Asset impairment charge	$	—		$	41.9

	Accelerated depreciation	6.9			6.9

	Workforce reduction charges	(1.7		)	5.5

	Other	0.5			0.4

	Total	$	5.7		$	54.7

	The asset impairment charge was based on the excess of the carrying value of the impacted asset group of $94 over its fair value of $52. The fair value was measured using discounted cash flows expected over the time the asset group would remain in use. The use of the discounted cash flows represents a level 3 measure under the fair value hierarchy.
	Accrued expenses for the plan were $6 as of September 30, 2014, and no cash payments were made during the three months or nine months ended September 30, 2014.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following:


		30-Sep-14								December 31, 2013
		LIFO			Non-		Total			LIFO			Non-		Total
					LIFO								LIFO
	At the lower of cost, determined on the FIFO or weighted-average cost methods, or market
	Raw materials	$	43.7		$	1.3	$	45		$	40.2		$	2.4	$	42.6

	Work in process	62.3			1		63.3			64.8			0.4		65.2

	Finished goods	162.5			37.1		199.6			148.7			42.3		191

	Supplies and other	—			13.6		13.6			—			13.6		13.6

		268.5			53		321.5			253.7			58.7		312.4

	Excess of FIFO or weighted-average cost over LIFO cost	(26.8		)	—		(26.8		)	(26.8		)	—		(26.8		)

	Total	$	241.7		$	53	$	294.7		$	226.9		$	58.7	$	285.6

Property_Plant_and_Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment consists of the following:


		30-Sep-14			31-Dec-13
	Land	$	3		$	4.5

	Buildings	79			104.3

	Machinery and equipment	499.1			617.2

	Construction in progress	51.9			46.5

		633			772.5

	Less accumulated depreciation	(340.2		)	(447.6		)
	Total	$	292.8		$	324.9

	Depreciation expense was $19 and $10 for the three months ended September 30, 2014 and 2013, respectively, and $37 and $31 for the nine months ended September 30, 2014 and 2013, respectively.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	The changes in the carrying amount of goodwill by business segment are as follows:


		Medical Devices			Surgical and Infection Prevention		Total
	Balance at December 31, 2013	$	686.3		$	743.8	$	1,430.10

	Currency translation adjustment	(3.7		)	2.6		(1.1		)

	Balance at September 30, 2014	$	682.6		$	746.4	$	1,429.00

	At September 30, 2014 and December 31, 2013, we had intangible assets with indefinite useful lives of $7 related to acquired in-process research and development.
	Intangible assets subject to amortization consist of the following:


		September 30, 2014					December 31, 2013
		Gross			Accumulated		Gross			Accumulated
		Carrying			Amortization		Carrying			Amortization
		Amount					Amount
	Trademarks	$	126.6		$	85.2	$	126.6		$	82.2

	Patents and acquired technologies	149.1			93.5		149.9			76.1

	Other	48.8			36.2		49.2			32.9

	Total	$	324.5		$	214.9	$	325.7		$	191.2

	Amortization expense for intangible assets was $8 and $7 for the three months ended September 30, 2014 and 2013, respectively, and $24 and $22 for the nine months ended September 30, 2014 and 2013, respectively.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	Accrued Expenses
	Accrued expenses consist of the following:


		30-Sep-14		31-Dec-13
	Accrued rebates	$	67	$	81.9

	Accrued litigation matters	16		25.7

	Accrued salaries and wages	38.8		37.3

	Accrued workforce reduction	5.5		—

	Accrued taxes - income and other	6		12.2

	Other	15.3		22.9

	Total	$	148.6	$	180

LongTerm_Liabilities

Long-Term Liabilities	9 Months Ended
	Sep. 30, 2014
Other Liabilities, Noncurrent [Abstract]	'
Long-Term Liabilities	'
	Long-Term Liabilities
	Long term liabilities consist of the following:


		30-Sep-14		31-Dec-13
	Deferred income taxes	$	87.6	$	90.5

	Taxes payable & other	4.9		4

	Total	$	92.5	$	94.5

Invested_Equity

Invested Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Invested Equity	'
	Invested Equity
	The amounts of Invested Equity from the beginning of the period to the end of the period are as follows:


		Nine Months Ended
		30-Sep-14						30-Sep-13
		Kimberly-Clark's Net Investment			Accumulated Other Comprehensive Income (Loss)			Kimberly-Clark's Net Investment			Accumulated Other Comprehensive Income (Loss)
	Balance at Beginning of Period	$	2,098.70		$	(19.6	)	$	2,045.60		$	10.1

	Net income	29.5			—			114.8			—

	Change in Kimberly-Clark's investment, net	(28.1		)	—			(48.8		)	—

	Other comprehensive income:
	Unrealized currency translation adjustments	—			(5.4		)	—			(12.4		)

	Cash flow hedges, net of tax	—			3.9			—			(5.6		)

	Balance at End of Period	$	2,100.10		$	(21.1	)	$	2,111.60		$	(7.9	)

Legal_Matters

Legal Matters	9 Months Ended
Legal Matters	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Legal Matters	'
	Legal Matters
	We are subject to various legal proceedings, claims and governmental inspections, audits or investigations pertaining to issues such as contract disputes, product liability, tax matters, patents and trademarks, advertising, governmental regulations, employment and other matters, including the matters described below. Under the terms of the distribution agreement we entered into with Kimberly-Clark prior to the Spin-off, legal proceedings, claims and other liabilities that are primarily related to our business will be our responsibility and we will be obligated to indemnify and hold Kimberly-Clark harmless for such matters. The only exception to this general obligation relates to the pain pump litigation referenced in the next paragraph below. Although the results of litigation and claims cannot be predicted with certainty, we believe that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, individually or in the aggregate, on our business, financial condition, results of operations or liquidity.
	We are one of several manufacturers of continuous infusion medical devices, such as our ON-Q PAINBUSTER pain pumps, that are involved in several different pending or threatened litigation matters from multiple plaintiffs alleging that use of the continuous infusion device to deliver anesthetics directly into a synovial joint after surgery resulted in postarthroscopic glenohumeral chondrolysis, or a disintegration of the cartilage covering the bones in the joint (typically, in the shoulder). Plaintiffs generally seek monetary damages and attorneys’ fees. While Kimberly-Clark is retaining the liabilities related to these matters, the distribution agreement between us and Kimberly-Clark provides that we will indemnify Kimberly-Clark for any such claims or causes of actions arising after the Spin-off.
	We operate in an industry characterized by extensive patent litigation and competitors may claim that our products infringe upon their intellectual property. Resolution of patent litigation or other intellectual property claims is typically time consuming and costly and can result in significant damage awards and injunctions that could prevent the manufacture and sale of the affected products or require us to make significant royalty payments in order to continue selling the affected products. At any given time we are involved as either a plaintiff or a defendant in a number of patent infringement actions, the outcomes of which may not be known for prolonged periods of time.
	We are subject to federal, state and local environmental protection laws and regulations with respect to our business operations and are operating in compliance with, or taking action aimed at ensuring compliance with, these laws and regulations. None of our compliance obligations with environmental protection laws and regulations, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition, results of operations or liquidity.

Objectives_and_Strategies_for_

Objectives and Strategies for Using Derivatives	9 Months Ended
Objectives and Strategies for Using Derivatives	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Objectives and Strategies for Using Derivatives	'
	Objectives and Strategies for Using Derivatives
	As a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest rates and commodity prices. We employ a number of practices to manage these risks, including operating activities and, where appropriate, the use of derivative instruments. In addition, Kimberly-Clark enters into derivative instruments for certain of its non-U.S. operations to hedge a portion of forecasted cash flows for raw materials, imports of intercompany finished goods and other intercompany goods and services denominated in U.S. dollars. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative instruments is recognized in earnings in the same period that the hedged exposure affects earnings. For hedging activity that is centrally managed by Kimberly-Clark, the associated derivative assets and liabilities and amounts recognized in accumulated other comprehensive income have not been included on our combined balance sheet. The portion of the amounts recognized to earnings for these commodity-based derivatives that relate to the business' operations have been allocated and included in cost of products sold on the combined income statement.
	We enter into derivative instruments to hedge a portion of forecasted cash flows denominated in Mexican pesos for purchases of intercompany services provided to our U.S. operations and for intercompany sales of inventory denominated in U.S. dollars made by our affiliates in Thailand. The derivative instruments used to manage these exposures are designated and qualify as cash flow hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged with primarily undesignated derivative instruments.
	Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowing. Translation exposure, which results from changes in translation rates between functional currencies and the U.S. dollar, is not hedged.
	The derivative liabilities for foreign exchange contracts at September 30, 2014 and December 31, 2013 were $1 and $5, respectively, and are included in the combined balance sheet in accrued expenses. The derivative assets for foreign exchange contracts as of September 30, 2014 and December 31, 2013 were not significant.
	For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative instrument is initially recorded in accumulated other comprehensive income (“AOCI”), net of related income taxes, and recognized in earnings in the same period that the hedged exposure affects earnings. These gains or losses recognized to earnings were not significant in the three and nine months ended September 30, 2014 and 2013. As of September 30, 2014, the aggregate notional values of outstanding foreign exchange derivative contracts designated as cash flow hedges were $55. Cash flow hedges resulted in no significant ineffectiveness in the three and nine months ended September 30, 2014 and 2013. For the three and nine months ended September 30, 2014 and 2013, no gains or losses were reclassified into earnings as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At September 30, 2014, amounts to be reclassified from AOCI during the next twelve months are not expected to be significant. The maximum maturity of cash flow hedges in place at September 30, 2014 is July 2015.
	Gains or losses on undesignated foreign exchange hedging instruments are immediately recognized in other income and expense, net. These gains or losses have not been significant for the three and nine months ended September 30, 2014 and 2013. The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. At September 30, 2014, the notional amount of these undesignated derivative instruments was $25.

Business_Segment_Information

Business Segment Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Business Segment Information	'
	Business Segment Information
	We are organized into two operating segments based on product groupings: S&IP and Medical Devices. These operating segments, which are also our reportable global business segments, were determined in accordance with how our executive management develops and executes global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. Segment management is evaluated on several factors, including operating profit. Segment operating profit excludes restructuring charges, transaction costs related to the Spin-off, and other income and expense, net.
	The principal sources of revenue in each global business segment are described below:

	•	S&IP provides healthcare supplies and solutions that target the prevention and management of healthcare associated infections. This segment has recognized brands across its portfolio of product offerings, including sterilization wrap, surgical drapes and gowns, facial protection, protective apparel and medical exam gloves. This business is also a global leader in education to prevent healthcare associated infections.

	•	Medical Devices provides a portfolio of innovative product offerings focused on pain management and respiratory and digestive health to improve patient outcomes and reduce the cost of care. These products include post-operative pain management solutions, minimally invasive interventional or chronic pain therapies, closed airway suction systems and enteral feeding tubes.
	Information concerning unaudited combined operations by business segment is presented in the following table:


		Three Months Ended								Nine Months Ended
		30-Sep								30-Sep
		2014			2013			Change		2014			2013			Change
	NET SALES
	Surgical and Infection Prevention	$	279.2		$	287		-2.7	%	$	840.2		$	860.1		-2.3	%

	Medical Devices	122.5			126.2			-2.9	%	373.5			366.8			1.8	%

	Corporate & Other	6.8			6.3			7.9	%	19			19.3			-1.6	%

	COMBINED TOTAL NET SALES	$	408.5		$	419.5		-2.6	%	$	1,232.70		$	1,246.20		-1.1	%


	OPERATING PROFIT
	Surgical and Infection Prevention	$	36.8		$	45.2		-18.6	%	$	118.1		$	113		4.5	%

	Medical Devices	20.4			28			-27.1	%	76.6			63.4			20.8	%

	Corporate & Other(a)	(44.8		)	(3.1		)	N.M.		(126.8		)	(10.6		)	N.M.

	Other (income) and expense, net	(0.7		)	(0.2		)	N.M.		(2.4		)	(1.9		)	N.M.

	COMBINED TOTAL OPERATING PROFIT	$	13.1		$	70.3		-81.4	%	$	70.3		$	167.7		-58.1	%

	N.M. - Not Meaningful

	(a)	Corporate & Other for the three and nine months ended September 30, 2014 includes $6 and $55, respectively, associated with Manufacturing Footprint Strategic Changes related to the S&IP business (see Note 3) and $35 and $61, respectively, of transaction costs associated with the Spin-off.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	A portion of our net sales results from sales to Kimberly-Clark subsidiaries and affiliates. Included in our combined financial statements are net sales from intercompany sales of $25 and $25 in the three months ended September 30, 2014 and 2013, respectively, and $70 and $69 in the nine months ended September 30, 2014 and 2013, respectively.
	During the three and nine months ended September 30, 2014 and 2013, we utilized manufacturing facilities and resources managed by affiliates of Kimberly-Clark to conduct our business. The expenses associated with these transactions, which primarily relate to production of semi-finished goods for our S&IP business, are included in cost of products sold in our combined income statement.
	Our combined financial statements include certain expenses of Kimberly-Clark which were allocated to us for certain functions, including general expenses related to supply chain, finance, legal, information technology, human resources, compliance, shared services, insurance, employee benefits and incentives and stock-based compensation. These expenses have been allocated to us on the basis of direct usage when identifiable, with the remainder allocated on the relative percentage of net sales or headcount. The total amount of these allocations from Kimberly-Clark was approximately as follows:


		Three Months Ended				Nine Months Ended
		30-Sep				30-Sep
		2014		2013		2014		2013
	Cost of products sold	$	8	$	6	$	20	$	19

	Selling and general expenses	7		15		38		45

	Research expenses	5		3		10		8

	Total	$	20	$	24	$	68	$	72

	We consider the expense allocation methodology and results to be reasonable for all periods presented. However, these allocations may not be indicative of the actual expenses we would have incurred as a separate, stand-alone public company or of the costs we will incur in the future. See Note 2, “Separation from Kimberly-Clark and Long-Term Debt” under the heading “Stand-Alone Public Company Costs” for further discussion.
	Historically, Kimberly-Clark has provided financing, cash management and other treasury services to us. In North America, our cash balances are swept by Kimberly-Clark, and historically, we have received funding from Kimberly-Clark for most of our operating and investing cash needs. Cash transferred to and from Kimberly-Clark has historically been recorded as intercompany cash. Intercompany cash, receivables and payables with Kimberly-Clark are reflected within Kimberly-Clark’s net investment in the accompanying combined financial statements.

Subsequent_Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	On October 7, 2014, the Board of Directors adopted the Halyard Health, Inc. Equity Participation Plan (the “Employee Plan”), which was approved by Kimberly-Clark as Halyard’s sole stockholder on October 7, 2014 and became effective as of November 1, 2014. The Employee Plan provides that the Compensation Committee of the Board of Directors may award to eligible recipients (as defined in the Employee Plan) as it may determine from time to time the following awards: stock options, stock appreciation rights, restricted stock (and in certain limited cases, unrestricted stock), restricted stock units, performance units and cash awards. Subject to the adjustment clauses in the Employee Plan, the maximum aggregate number of shares of Halyard common stock that may be subject to awards granted under the Employee Plan is 4,500,000.
	On October 7, 2014, the Board of Directors adopted the Halyard Health, Inc. Outside Directors’ Compensation Plan (the “Director Plan”), which was approved by Kimberly-Clark as Halyard’s sole stockholder on October 7, 2014 and became effective as of November 1, 2014. The Director Plan provides that the Board may award to directors as it may determine from time to time the following awards: stock options, stock appreciation rights, restricted stock (and in certain limited cases, unrestricted stock), restricted stock units, performance units and cash awards. The Director Plan also provides that each director’s annual retainer will be paid under the Director Plan, and the director may elect to receive such compensation as a cash award or in the form of stock options. Subject to the adjustment clauses in the Director Plan, the maximum number of shares of Halyard common stock that may be subject to awards granted under the Director Plan is 400,000 shares.

Accounting_Policies_Policies

Accounting Policies (Policies)	9 Months Ended
Accounting Policies (Policies)	Sep. 30, 2014
Accounting Policies [Abstract]	'
Background and Basis of Presentation	'
	Background and Basis of Presentation
	Halyard Health, Inc. is a global business which seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. Our products and solutions are designed to address some of today’s most important healthcare needs, namely, preventing infections and reducing the use of narcotics while helping patients move from surgery to recovery. We market and support the efficacy, safety and economic benefit of our products with a significant body of clinical evidence.
	References to “Halyard,” “we,” “our” and “us” refer to the health care operations that relate to Kimberly-Clark's health care business. References to “Kimberly-Clark” mean Kimberly-Clark Corporation, a Delaware corporation, and its subsidiaries, other than Halyard, unless the context otherwise requires. Dollar amounts are reported in millions, except per share amounts, unless otherwise noted.
	In November 2013, Kimberly-Clark announced that its Board of Directors authorized management to evaluate a potential tax-free spin-off of its health care business (the “Spin-off”). Halyard Health, Inc. was incorporated in Delaware on February 25, 2014 for the purpose of holding the health care business following the separation. A Form 10 initial registration statement was filed in May 2014 with the Securities and Exchange Commission (“SEC”) to register our business as a stand-alone public company. The Form 10 registration statement, as amended, was declared effective by the SEC on October 17, 2014. The Spin-off was completed on October 31, 2014 and Kimberly-Clark’s health care business became Halyard Health, Inc. During the three and nine months ended September 30, 2014, $35 and $61, respectively, was recorded in selling and general expenses for transaction costs associated with the spin-off. See Note 2, “Separation from Kimberly-Clark and Long-Term Debt” for further discussion.
	These unaudited condensed combined interim financial statements represent the global operations of Kimberly-Clark's health care business, and have been prepared on a carve-out basis from the operations of Kimberly-Clark’s health care business. The combined financial statements are derived from Kimberly-Clark's consolidated financial statements and accounting records, and reflect our financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected.
Annual Goodwill Impairment Test	'
	Annual Goodwill Impairment Test
	Goodwill is tested for impairment annually and whenever events and circumstances indicate that impairment may have occurred. For 2014 we have completed the required annual testing of goodwill for impairment for all reporting units using the beginning of the third quarter 2014 as the measurement date. The fair value for all reporting units was in excess of the book value. The fair value of our Medical Devices unit exceeded the carrying value of its net assets by 76%; the fair value of our Surgical and Infection Prevention (“S&IP”) unit exceeded the carrying value of its net assets by 6%, primarily because of the incremental stand-alone public company corporate and ongoing costs described in Note 2 “Separation from Kimberly-Clark and Long-Term Debt” under the heading “Stand-Alone Public Company Costs.”
	The fair value determination utilized key assumptions regarding growth of the business and stand-alone public company corporate and ongoing costs, each of which required significant management judgment, including estimated future sales volumes, selling prices and costs, changes in working capital, and investments in property and equipment. These assumptions and estimates were based upon our historical experience and projections of future activity. In addition, the selection of the discount rate used to determine fair value was based upon current market rates and our current cost of financing. There can be no assurance that the assumptions and estimates made for purposes of the annual goodwill impairment test will prove to be accurate. Volatility in the equity and debt markets, or increases in interest rates, could result in a higher discount rate. Changes in sales volumes, selling prices and costs of goods sold, additional stand-alone public company costs, and increases in interest rates could cause changes in our forecasted cash flows. Unfavorable changes in any of the factors described above could result in a goodwill impairment charge in the future.
New Accounting Standards	'
	New Accounting Standards
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The standard is effective for public entities for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The effects of this standard on our financial position, results of operations and cash flows are not yet known.

Manufacturing_Footprint_Strate1

Manufacturing Footprint Strategic Changes (Tables)	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Pre-tax charges for the manufacturing footprint strategic changes	'
	Through September 30, 2014, cumulative pre-tax charges for the manufacturing footprint strategic changes were $55 ($38 after-tax), consisting the following:


		Three Months Ended September 30, 2014			Nine Months Ended September 30, 2014
	Asset impairment charge	$	—		$	41.9

	Accelerated depreciation	6.9			6.9

	Workforce reduction charges	(1.7		)	5.5

	Other	0.5			0.4

	Total	$	5.7		$	54.7

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of inventories	'
	Inventories consist of the following:


		30-Sep-14								December 31, 2013
		LIFO			Non-		Total			LIFO			Non-		Total
					LIFO								LIFO
	At the lower of cost, determined on the FIFO or weighted-average cost methods, or market
	Raw materials	$	43.7		$	1.3	$	45		$	40.2		$	2.4	$	42.6

	Work in process	62.3			1		63.3			64.8			0.4		65.2

	Finished goods	162.5			37.1		199.6			148.7			42.3		191

	Supplies and other	—			13.6		13.6			—			13.6		13.6

		268.5			53		321.5			253.7			58.7		312.4

	Excess of FIFO or weighted-average cost over LIFO cost	(26.8		)	—		(26.8		)	(26.8		)	—		(26.8		)

	Total	$	241.7		$	53	$	294.7		$	226.9		$	58.7	$	285.6

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of property, plant and equipment	'
	Property, plant and equipment consists of the following:


		30-Sep-14			31-Dec-13
	Land	$	3		$	4.5

	Buildings	79			104.3

	Machinery and equipment	499.1			617.2

	Construction in progress	51.9			46.5

		633			772.5

	Less accumulated depreciation	(340.2		)	(447.6		)
	Total	$	292.8		$	324.9

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the carrying amount of goodwill by business segment	'
	The changes in the carrying amount of goodwill by business segment are as follows:


		Medical Devices			Surgical and Infection Prevention		Total
	Balance at December 31, 2013	$	686.3		$	743.8	$	1,430.10

	Currency translation adjustment	(3.7		)	2.6		(1.1		)

	Balance at September 30, 2014	$	682.6		$	746.4	$	1,429.00

Schedule of intangible assets subject to amortization	'
	Intangible assets subject to amortization consist of the following:


		September 30, 2014					December 31, 2013
		Gross			Accumulated		Gross			Accumulated
		Carrying			Amortization		Carrying			Amortization
		Amount					Amount
	Trademarks	$	126.6		$	85.2	$	126.6		$	82.2

	Patents and acquired technologies	149.1			93.5		149.9			76.1

	Other	48.8			36.2		49.2			32.9

	Total	$	324.5		$	214.9	$	325.7		$	191.2

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of accrued expenses	'
	Accrued expenses consist of the following:


		30-Sep-14		31-Dec-13
	Accrued rebates	$	67	$	81.9

	Accrued litigation matters	16		25.7

	Accrued salaries and wages	38.8		37.3

	Accrued workforce reduction	5.5		—

	Accrued taxes - income and other	6		12.2

	Other	15.3		22.9

	Total	$	148.6	$	180

LongTerm_Liabilities_Tables

Long-Term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Other Liabilities, Noncurrent [Abstract]	'
Schedule of long-term liabilities	'
	Long term liabilities consist of the following:


		30-Sep-14		31-Dec-13
	Deferred income taxes	$	87.6	$	90.5

	Taxes payable & other	4.9		4

	Total	$	92.5	$	94.5

Invested_Equity_Tables

Invested Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Schedule of changes in Invested Equity	'
	The amounts of Invested Equity from the beginning of the period to the end of the period are as follows:


		Nine Months Ended
		30-Sep-14						30-Sep-13
		Kimberly-Clark's Net Investment			Accumulated Other Comprehensive Income (Loss)			Kimberly-Clark's Net Investment			Accumulated Other Comprehensive Income (Loss)
	Balance at Beginning of Period	$	2,098.70		$	(19.6	)	$	2,045.60		$	10.1

	Net income	29.5			—			114.8			—

	Change in Kimberly-Clark's investment, net	(28.1		)	—			(48.8		)	—

	Other comprehensive income:
	Unrealized currency translation adjustments	—			(5.4		)	—			(12.4		)

	Cash flow hedges, net of tax	—			3.9			—			(5.6		)

	Balance at End of Period	$	2,100.10		$	(21.1	)	$	2,111.60		$	(7.9	)

Business_Segment_Information_T

Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Information concerning unaudited combined operations by business segment	'
	Information concerning unaudited combined operations by business segment is presented in the following table:


		Three Months Ended								Nine Months Ended
		30-Sep								30-Sep
		2014			2013			Change		2014			2013			Change
	NET SALES
	Surgical and Infection Prevention	$	279.2		$	287		-2.7	%	$	840.2		$	860.1		-2.3	%

	Medical Devices	122.5			126.2			-2.9	%	373.5			366.8			1.8	%

	Corporate & Other	6.8			6.3			7.9	%	19			19.3			-1.6	%

	COMBINED TOTAL NET SALES	$	408.5		$	419.5		-2.6	%	$	1,232.70		$	1,246.20		-1.1	%


	OPERATING PROFIT
	Surgical and Infection Prevention	$	36.8		$	45.2		-18.6	%	$	118.1		$	113		4.5	%

	Medical Devices	20.4			28			-27.1	%	76.6			63.4			20.8	%

	Corporate & Other(a)	(44.8		)	(3.1		)	N.M.		(126.8		)	(10.6		)	N.M.

	Other (income) and expense, net	(0.7		)	(0.2		)	N.M.		(2.4		)	(1.9		)	N.M.

	COMBINED TOTAL OPERATING PROFIT	$	13.1		$	70.3		-81.4	%	$	70.3		$	167.7		-58.1	%

	N.M. - Not Meaningful

	(a)	Corporate & Other for the three and nine months ended September 30, 2014 includes $6 and $55, respectively, associated with Manufacturing Footprint Strategic Changes related to the S&IP business (see Note 3) and $35 and $61, respectively, of transaction costs associated with the Spin-off.

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Schedule of expenses allocated from Kimberly-Clark	'
	The total amount of these allocations from Kimberly-Clark was approximately as follows:


		Three Months Ended				Nine Months Ended
		30-Sep				30-Sep
		2014		2013		2014		2013
	Cost of products sold	$	8	$	6	$	20	$	19

	Selling and general expenses	7		15		38		45

	Research expenses	5		3		10		8

	Total	$	20	$	24	$	68	$	72

Accounting_Policies_Background

Accounting Policies - Background and Basis of Presentation (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Selling and general expenses	$111.30	$82.50	$298.10	$266.90

Accounting_Policies_Annual_Goo

Accounting Policies - Annual Goodwill Impairment Test (Details)	Sep. 30, 2014
Medical Devices	'
Goodwill [Line Items]	'
Excess of fair value over carrying value, percentage	76.00%
Surgical and Infection Prevention	'
Goodwill [Line Items]	'
Excess of fair value over carrying value, percentage	6.00%

Separation_from_KimberlyClark_1

Separation from Kimberly-Clark and Long-Term Debt - Separation from Kimberly-Clark (Details) (Subsequent Event, USD $)	0 Months Ended
	Oct. 31, 2014	Oct. 31, 2014	Oct. 17, 2014	Oct. 31, 2014
	Kimberly Clark and Affiliates	Secured debt	6.25% Senior Notes	Senior term loan
		Term loan facility	Unsecured debt	Secured debt
Business Acquisition [Line Items]	'	'	'	'
Aggregate principal amount	'	'	$250,000,000	$390,000,000
Stated interest rate	'	'	6.25%	'
Borrowing capacity	'	390,000,000	'	'
Cash distribution	$680,000,000	'	'	'

Separation_from_KimberlyClark_2

Separation from Kimberly-Clark and Long-Term Debt - Stand-Alone Public Company Costs (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2015
In Millions, unless otherwise specified	Spin-off	Spin-off	Forecasted
	Minimum	Maximum
Business Acquisition [Line Items]	'	'	'
Aggregate annual expenses	'	'	$146
Incremental cash expenses	'	'	40
Depreciation and amortization	'	'	11
Additional ongoing net expenses	'	'	29
Transitional costs	$60	$75	'

Separation_from_KimberlyClark_3

Separation from Kimberly-Clark and Long-Term Debt - Senior Unsecured Notes, Term Loan and Revolving Credit Facilities (Details) (USD $)

3 Months Ended

0 Months Ended

Mar. 31, 2015

Oct. 17, 2014

Oct. 31, 2014

Oct. 17, 2014

Forecasted

Subsequent Event

Swingline sub-facility

Secured debt

6.25% Senior Notes

LIBOR

Base rate

Leverage Ratio, Less than 2.25

LIBOR

Base rate

Line of credit

Revolving credit facility

Letter of credit

Swingline sub-facility

Term loan facility

Unsecured debt

Minimum

Maximum

Minimum

Maximum

LIBOR

U.S. federal funds effective rate

One month LIBOR Rate

Base rate

Debt Instrument [Line Items]

Aggregate principal amount

$250,000,000

Stated interest rate

6.25%

Borrowing capacity

$640,000,000

$250,000,000

$75,000,000

$25,000,000

$390,000,000

Term of credit facility

'5 years

'7 years

Basis spread on variable rate

1.75%

2.50%

0.75%

1.50%

2.25%

1.25%

3.25%

0.50%

1.00%

2.25%

Quarterly amortization payments

0.25%

Unused capacity, commitment fee percentage

0.40%

0.25%

Consolidated total leverage ratio

2.25

Manufacturing_Footprint_Strate2

Manufacturing Footprint Strategic Changes (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

In Millions, unless otherwise specified

Disposable glove facilities exit plan

Asset impairment and accelerated depreciation charges

Workforce reduction and other exit costs

Asset impairment charge

Accelerated depreciation

Workforce reduction charges

Other

Employee

Disposable glove facilities exit plan

Restructuring Cost and Reserve [Line Items]

Expected number of positions eliminated

3,000

Estimated cumulative charges

$70

$55

$15

Estimated cumulative charges, after-tax

Restructuring charges

5.7

54.7

41.9

6.9

-1.7

5.5

0.5

0.4

Restructuring charges, net of tax

Carrying value of impacted asset group

Fair value of impacted asset group

Accrued workforce reduction

$5.50

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
LIFO	'	'
Raw materials	$43.70	$40.20
Work in process	62.3	64.8
Finished goods	162.5	148.7
Supplies and other	0	0
Inventory, gross	268.5	253.7
Excess of FIFO or weighted-average cost over LIFO cost	-26.8	-26.8
Inventories, net	241.7	226.9
Non- LIFO	'	'
Raw materials	1.3	2.4
Work in process	1	0.4
Finished goods	37.1	42.3
Supplies and other	13.6	13.6
Inventory, gross	53	58.7
Inventories, net	53	58.7
Total	'	'
Raw materials	45	42.6
Work in process	63.3	65.2
Finished goods	199.6	191
Supplies and other	13.6	13.6
Inventory, gross	321.5	312.4
Excess of FIFO or weighted-average cost over LIFO cost	-26.8	-26.8
Inventories, net	$294.70	$285.60

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	$633	'	$633	'	$772.50
Less accumulated depreciation	-340.2	'	-340.2	'	-447.6
Total	292.8	'	292.8	'	324.9
Depreciation expense	19	10	37	31	'
Land	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	3	'	3	'	4.5
Buildings	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	79	'	79	'	104.3
Machinery and equipment	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	499.1	'	499.1	'	617.2
Construction in progress	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	$51.90	'	$51.90	'	$46.50

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Schedule of Goodwill (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Goodwill [Roll Forward]	'
Balance at beginning of period	$1,430.10
Currency translation adjustment	-1.1
Balance at end of period	1,429
Medical Devices	'
Goodwill [Roll Forward]	'
Balance at beginning of period	686.3
Currency translation adjustment	-3.7
Balance at end of period	682.6
Surgical and Infection Prevention	'
Goodwill [Roll Forward]	'
Balance at beginning of period	743.8
Currency translation adjustment	2.6
Balance at end of period	$746.40

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$324.50	$325.70
Accumulated Amortization	214.9	191.2
Trademarks	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	126.6	126.6
Accumulated Amortization	85.2	82.2
Patents and acquired technologies	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	149.1	149.9
Accumulated Amortization	93.5	76.1
Other	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	48.8	49.2
Accumulated Amortization	$36.20	$32.90

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Additional Disclosures (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	In-process research and development	In-process research and development
Indefinite-lived Intangible Assets [Line Items]	'	'	'	'	'	'
Intangible assets with indefinite useful lives	'	'	'	'	$7	$7
Amortization expense	$8	$7	$24	$22	'	'

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]	'	'
Accrued rebates	$67	$81.90
Accrued litigation matters	16	25.7
Accrued salaries and wages	38.8	37.3
Accrued workforce reduction	5.5	0
Accrued taxes - income and other	6	12.2
Other	15.3	22.9
Total	$148.60	$180

LongTerm_Liabilities_Details

Long-Term Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Other Liabilities, Noncurrent [Abstract]	'	'
Deferred income taxes	$87.60	$90.50
Taxes payable & other	4.9	4
Total	$92.50	$94.50

Invested_Equity_Details

Invested Equity (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Invested Equity at beginning of period	'	'	$2,079.10	'
Net income	-7.4	47.9	29.5	114.8
Unrealized currency translation adjustments	-9.2	1.6	-5.4	-12.4
Cash flow hedges, net of tax	-0.3	-1.3	3.9	-5.6
Invested Equity at end of period	2,079	'	2,079	'
Kimberly-Clark's Net Investment	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Invested Equity at beginning of period	'	'	2,098.70	2,045.60
Net income	'	'	29.5	114.8
Change in Kimberly-Clark's investment, net	'	'	-28.1	-48.8
Unrealized currency translation adjustments	'	'	0	0
Cash flow hedges, net of tax	'	'	0	0
Invested Equity at end of period	2,100.10	2,111.60	2,100.10	2,111.60
Accumulated Other Comprehensive Income (Loss)	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Invested Equity at beginning of period	'	'	-19.6	10.1
Net income	'	'	0	0
Change in Kimberly-Clark's investment, net	'	'	0	0
Unrealized currency translation adjustments	'	'	-5.4	-12.4
Cash flow hedges, net of tax	'	'	3.9	-5.6
Invested Equity at end of period	($21.10)	($7.90)	($21.10)	($7.90)

Objectives_and_Strategies_for_1

Objectives and Strategies for Using Derivatives (Details) (Foreign exchange contracts, USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Derivative [Line Items]	'	'
Derivative liability	$1	$5
Undesignated hedging instruments	'	'
Derivative [Line Items]	'	'
Aggregate notional amount	25	'
Cash flow hedges	'	'
Derivative [Line Items]	'	'
Aggregate notional amount	$55	'

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
	Sep. 30, 2014	Sep. 30, 2013	segment	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Number of operating segments	'	'	2	'
Net sales	$408.50	$419.50	$1,232.70	$1,246.20
Operating Income (Loss)	13.1	70.3	70.3	167.7
Other (income) and expense, net	-0.7	-0.2	-2.4	-1.9
Selling and general expenses	111.3	82.5	298.1	266.9
Net Sales	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Percent change	-2.60%	'	-1.10%	'
Operating Profit	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Percent change	-81.40%	'	-58.10%	'
Surgical and Infection Prevention \| Spin-off	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Selling and general expenses	35	'	61	'
Surgical and Infection Prevention \| Disposable glove facilities exit plan	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Selling and general expenses	6	'	55	'
Operating segments \| Surgical and Infection Prevention	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	279.2	287	840.2	860.1
Operating Income (Loss)	36.8	45.2	118.1	113
Operating segments \| Surgical and Infection Prevention \| Net Sales	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Percent change	-2.70%	'	-2.30%	'
Operating segments \| Surgical and Infection Prevention \| Operating Profit	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Percent change	-18.60%	'	4.50%	'
Operating segments \| Medical Devices	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	122.5	126.2	373.5	366.8
Operating Income (Loss)	20.4	28	76.6	63.4
Operating segments \| Medical Devices \| Net Sales	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Percent change	-2.90%	'	1.80%	'
Operating segments \| Medical Devices \| Operating Profit	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Percent change	-27.10%	'	20.80%	'
Corporate, non-segment	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	6.8	6.3	19	19.3
Operating Income (Loss)	($44.80)	($3.10)	($126.80)	($10.60)
Corporate, non-segment \| Net Sales	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Percent change	7.90%	'	-1.60%	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Related Party Transaction [Line Items]	'	'	'	'
Net sales	$408.50	$419.50	$1,232.70	$1,246.20
Kimberly Clark and Affiliates \| Affiliated entity	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Net sales	24.8	24.5	70.4	69
Allocated expenses	20	24	68	72
Kimberly Clark and Affiliates \| Affiliated entity \| Cost of products sold	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Allocated expenses	8	6	20	19
Kimberly Clark and Affiliates \| Affiliated entity \| Selling and general expenses	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Allocated expenses	7	15	38	45
Kimberly Clark and Affiliates \| Affiliated entity \| Research expenses	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Allocated expenses	$5	$3	$10	$8

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event)	Oct. 07, 2014
Employee Plan	'
Subsequent Event [Line Items]	'
Share-based compensation, number of shares authorized	4,500,000
Director Plan	'
Subsequent Event [Line Items]	'
Share-based compensation, number of shares authorized	400,000